Scholarlink

Introduction <p>Recent trials have expanded eligibility for omission of sentinel lymph node biopsy (SLNB) in early-stage breast cancer, while adjuvant cyclin-dependent kinase 4/6 (CDK4/6) inhibitors improve outcomes in patients with high-risk features that often rely on pathologic nodal status. The impact of SLNB omission on identifying candidates for CDK4/6 inhibitor therapy remains unclear. We evaluated how omission affects eligibility under Choosing Wisely and American Society of Clinical Oncology (ASCO) criteria.</p> Methods <p>From the National Cancer Database (2018–2022), we identified women aged ≥ 50 years with hormone-receptor-positive, HER2-negative, clinical T1–2N0M0 breast cancer treated with upfront surgery and SLNB. Omission-eligible cohorts were defined based on Choosing Wisely and ASCO criteria. CDK4/6 inhibitor (abemaciclib and ribociclib) eligibility was assessed using tumor features alone (modeling omission), SLNB findings, and axillary lymph node dissection (ALND) findings. Multivariable logistic regression identified predictors of SLNB determining eligibility.</p> Results <p>Among 150,629 patients, 73% met SLNB omission criteria. Positive SLNs were found in 9–10%, and only 2% had pN2–3 disease. SLNB omission would miss 4% (abemaciclib) and 8% (ribociclib) of eligible patients in the Choosing Wisely cohort, and 1 and 8%, respectively, in the ASCO cohort. ALND increased candidacy by only 1%. Approximately 13 SLNBs were required to identify one CDK4/6-eligible patient, and 299 SLNBs were required to identify one patient expected to derive a 5-year invasive disease-free survival benefit.</p> Conclusions <p>SLNB omission excludes few patients eligible for adjuvant CDK4/6 inhibitor therapy. These findings support shared decision-making and suggest SLNB should not be performed solely to determine CDK4/6 eligibility.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Role of Sentinel Node Surgery in Identifying Candidates for Adjuvant CDK4/6 Inhibitors: Implications of Choosing Wisely and ASCO Omission Criteria

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年7月8日

查看全文
  • Austin D. Williams,
  • Walker Lyons,
  • Lindsey B. Taylor,
  • Cecilia Chang,
  • Angela Jain,
  • Melissa McShane,
  • Allison A. Aggon,
  • Alycia So,
  • Jennifer Winn,
  • Richard J. Bleicher

摘要

Introduction

Recent trials have expanded eligibility for omission of sentinel lymph node biopsy (SLNB) in early-stage breast cancer, while adjuvant cyclin-dependent kinase 4/6 (CDK4/6) inhibitors improve outcomes in patients with high-risk features that often rely on pathologic nodal status. The impact of SLNB omission on identifying candidates for CDK4/6 inhibitor therapy remains unclear. We evaluated how omission affects eligibility under Choosing Wisely and American Society of Clinical Oncology (ASCO) criteria.

Methods

From the National Cancer Database (2018–2022), we identified women aged ≥ 50 years with hormone-receptor-positive, HER2-negative, clinical T1–2N0M0 breast cancer treated with upfront surgery and SLNB. Omission-eligible cohorts were defined based on Choosing Wisely and ASCO criteria. CDK4/6 inhibitor (abemaciclib and ribociclib) eligibility was assessed using tumor features alone (modeling omission), SLNB findings, and axillary lymph node dissection (ALND) findings. Multivariable logistic regression identified predictors of SLNB determining eligibility.

Results

Among 150,629 patients, 73% met SLNB omission criteria. Positive SLNs were found in 9–10%, and only 2% had pN2–3 disease. SLNB omission would miss 4% (abemaciclib) and 8% (ribociclib) of eligible patients in the Choosing Wisely cohort, and 1 and 8%, respectively, in the ASCO cohort. ALND increased candidacy by only 1%. Approximately 13 SLNBs were required to identify one CDK4/6-eligible patient, and 299 SLNBs were required to identify one patient expected to derive a 5-year invasive disease-free survival benefit.

Conclusions

SLNB omission excludes few patients eligible for adjuvant CDK4/6 inhibitor therapy. These findings support shared decision-making and suggest SLNB should not be performed solely to determine CDK4/6 eligibility.